Amylyx Pharmaceuticals, Inc. AMLX Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Amylyx Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The official record: Amylyx Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amylyx Pharmaceuticals, Inc.'s total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amylyx Pharmaceuticals, Inc.'s total liabilities & equity?
- Amylyx Pharmaceuticals, Inc. (AMLX) reported total liabilities & equity of $293.6M in Q1 2026.
- How has Amylyx Pharmaceuticals, Inc.'s total liabilities & equity changed year-over-year?
- Amylyx Pharmaceuticals, Inc.'s total liabilities & equity increased by 33.7% year-over-year, from $219.68M to $293.6M.
- What is the long-term trend for Amylyx Pharmaceuticals, Inc.'s total liabilities & equity?
- Over 4 years (2021 to 2025), Amylyx Pharmaceuticals, Inc.'s total liabilities & equity has grown at a 33.2% compound annual growth rate (CAGR), from $105.61M to $332.65M.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.